000			nab a22 7a 4500
999			_c17946 _d17946
003			PC17946
005			20250424062735.0
008			250422b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aenf
100			_92462 _aSánchez Zapardiel, Elena _eInmunología
100			_91509 _aMancebo Sierra, Esther _eInmunología
100			_9661 _aSerrano Hernández, Antonio _eInmunología
100			_92010 _aCastro Panete, María José _eInmunología
100			_93430 _aUtrero Rico, Alberto _d _eInstituto de investigación imas12
100			_91321 _aAndrés Belmonte, Amado _eNefrología
100			_9576 _aMorales Cerdán, José María _eNefrología
100			_91510 _aPaz Artal, Estela _eInmunología
245	0	0	_aIsolated De Novo Antiendothelial Cell Antibodies and Kidney Transplant Rejection. _h[artículo]
260			_bAmerican journal of kidney diseases : the official journal of the National Kidney Foundation, _c2016
300			_a68(6):933-43.
500			_aFormato Vancouver: Sánchez Zapardiel E, Mancebo E, Díaz Ordoñez M, de Jorge Huerta L, Ruiz Martínez L, Serrano A et al. Isolated De Novo Antiendothelial Cell Antibodies and Kidney Transplant Rejection. Am J Kidney Dis. 2016 Dec;68(6):933-43.
501			_aPMID: 27599627
504			_aContiene 34 referencias
520			_aBackground: Studies analyzing the role of antiendothelial cell antibodies (AECAs) in large series of kidney transplant recipients are scarce, and HLA, MHC (major histocompatibility complex) class I-related chain A (MICA), and angiotensin II type 1 receptor have not been formally excluded as targets. Study design: Retrospective study of a cohort of kidney transplant recipients. Setting & participants: 324 kidney transplant recipients who were negative for anti-HLA, anti-MICA, and anti-angiotensin II type 1 receptor antibodies were tested for AECAs in pre- and posttransplantation serum samples. Predictors: AECA-positive (preformed [pre+/post+] vs de novo [pre-/post+]) versus AECA-negative (pre-/post-) before or after transplantation. Outcomes: Patient mortality, transplant loss, and acute rejection events. Results: 66 (20%) patients were AECA positive (39 [12%] preformed, 27 [8%] de novo) and 258 (80%) were AECA negative. During a follow-up of 10 years, 7 (18%) AECA pre+/post+ patients had rejections compared with 14 (52%) AECA pre-/post+ and 57 (22%) AECA pre-/post- recipients (OR, 3.80; P=0.001). AECA pre-/post+ status emerged as an independent risk factor for transplant rejection compared to the AECA pre-/post- group (OR, 5.17; P<0.001). However, AECA pre+/post+ and AECA pre-/post+ patients did not show higher risk for either patient death (ORs of 1.49 [P=0.7] and 1.06 [P=0.9], respectively) or transplant loss (ORs of 1.22 and 0.86, respectively; P for both = 0.8) compared to the AECA pre-/post- population. Limitations: Retrospective study. Posttransplantation sera were collected before or after rejection, entailing a nearly cross-sectional relationship between the exposure and outcome. Lack of identification of precise antigens for AECAs. Conclusions: De novo AECAs may be associated with rejection. These antibodies might serve as biomarkers of endothelium damage in kidney transplant recipients.
710			_9395 _aServicio de Inmunología
710			_986 _aServicio de Nefrología
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17946.pdf _ySolicitar documento
942			_2ddc _cART _n0